| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $9.1M | -54.4% |
| SG&A Expense | $20.4M | +68.5% |
| Operating Income | -$29.5M | +8.1% |
| Net Income | -$26.6M | +27.7% |
| EPS (Basic) | -$1.67 | -198.2% |
| EPS (Diluted) | -$1.67 | -198.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $29.2M | +11.7% |
| Short-term Investments | $12.1M | — |
| Current Assets | $49.0M | +58.2% |
| Total Assets | $49.1M | +55.2% |
| Current Liabilities | $18.9M | -21.5% |
| Total Liabilities | $18.9M | -21.9% |
| Stockholders' Equity | $30.2M | +306.4% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$31.3M | -9.6% |
| Capital Expenditures | $24K | -66.7% |
| Investing Cash Flow | -$12.1M | — |
| Financing Cash Flow | $46.5M | +3.1% |
| Free Cash Flow | -$31.3M | -9.4% |